Partners
Myeloid
Industry Partner
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
Our proprietary ATAK™ platform is designed to designed to turn myeloid cells against tumors. These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforcing the anti-tumor immune response, culminating in cancer eradication.
Promega
Program Partner
We share your passion for science. Promega is committed to excellence in technologies for cellular therapy programs (e.g., CART cells and T cell receptor modifications) as well as immuno-oncology (e.g., LAG-3, TIM-3, ICOS, CD28, ADCC/ADCP and bi-specific mAbs). All assays are based on bright and sensitive firefly or NanoLuc luciferases. Let’s collaborate.
Maxcyte
Program Partner
MaxCyte is a leading provider of cell-engineering platform technologies driving the nextgeneration of cell-based therapies.
MaxCyte has granted 13 strategic platform licenses to leading cellbased therapy developers. Through 2020, MaxCyte has granted licenses for 140+ cell therapy programs, with 100+ licensed for clinical use. Our Flow Electroporation® technology
and next-generation ExPERT® platform enable our partners to accelerate, streamline, and improve the drug development process.
Learn more at www.maxcyte.com